By Felix Myhill – RegMedNet –
Whether or not to administer CAR-T cell therapy to cancer patients who go into remission during the therapy manufacturing window has long been a largely uninformed decision. The findings of a recent study reveal that administering CAR-T therapy to patients in remission from large B-cell lymphoma does not produce adverse health effects.
CAR-T cell therapy is an immunotherapy that consists of a patient’s T cells that have been extracted and engineered to display chimeric antigen receptors (CARs) that target and bind cancer cell-specific proteins. These CAR-T cells are expanded in the laboratory and infused back into the patient, where they should continue to expand and kill cancer cells that possess the antigens that the CAR-T cells target.
